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Introduction 
Granulocyte and granulocyte-macrophage colony stimulat- 
ing factors (G-CSF and GM-CSF) are haematopoietic 
growth factors. They stimulate haematopoietic progenitor 
cells to proliferate and differentiate into granulocytes and 
macrophages and are used prophylactically during the 
period of bone-marrow suppression after chemotherapy (1). 
Anecdotal reports have suggested an increased risk of 
pneumonitis in patients treated with cytotoxic chemo- 
therapy and G/GM-CSF (2-7). We report our experience in 
five patients with pneumonitis related to administration of 
cytotoxic drugs and G/GM-CSF and review the earlier 
literature, including our preliminary report (8). 
Methods 
BRONCHOALVEOLAR LAVAGE 
Bronchoalveolar lavage was performed under local anaes- 
thesia. Four aliquots of 50 ml sterile saline solution were 
instilled. The fluid was recovered by gentle aspiration into 
sterile siliconized jars. T-lymphocyte subsets were counted 
by indirect immunofluorescence using monoclonal anti- 
bodies (OKT3, OKT4 and OKT8; Ortho Diagnostics, 
Raritan, New Jersey, U.S.A.). 
CHEST RADIOLOGICAL IMAGING 
High resolution chest computed tomography (HRCT) 
scans were performed on an Elscint model (Elite+CT scan: 
Elscint, Haifa, Israel). 
PATIENTS 
We performed a retrospective study of five cases observed 
in the Department of Pulmonary Medicine of Foch 
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Hospital over 3 years. During this period, 57 patients with 
lymphoma received a comparable chemotherapy regimen in 
the Division of Haematology of Necker Hospital, and 21 in 
the Department of Haematology/Oncology of Foch 
Hospital. 
Case Reports 
All five patients (three men, two women) were non- 
smokers. The median age was 43 years (range 33-70). All 
patients had aggressive non-Hodgkin’s lymphoma (four 
diffuse large B cell, and one with diffuse large T cell). Three 
patients had mediastinal adenopathy, and one (patient 4) 
had histologically demonstrated lymphomatous pulmonary 
involvement. All were seronegative for Human Immuno- 
deficiency Virus and Human T-cell Leukaemia Virus type I. 
The Karnofsky performance status was 90% for four 
patients and 80% in one case (patient no. 2). All had an 
unremarkable pulmonary history and normal echocardio- 
grams. The chemotherapy protocol was identical in all 
patients. Each 3-weekly course consisted of doxorubicin 
75 mg m - 2 (day l), cyclophosphamide 1200 mg m - ’ (day 
l), vindesine 2 mg m- 2 (day 1 and day 5), bleomycin 
sulfate 10 mg daily (day 1 and day 5), methylprednisolone 
60 mg m - 2 (day 1 to day 5) and intrathecal methotrexate 
15 mg (day 1). In addition each course was followed 
prophylactically by a dose of non-glycosylated G-CSF 
5pg kg-’ day-’ S.C. (patients 1, 3, and 5) or GM-CSF 
300,ug day- ’ S.C. (patients 2 and 4) from day 6 to 
day 13. 
After the second (patients 1 and 4), third (patient 3), and 
the fourth (patients 2 and 5) cycles of chemotherapy, the 
course was marked by the abrupt onset (within 2448 h) of 
very rapidly increasing dyspnoea and fever above 39°C. 
These symptoms occurred on average 10 days (range 8-16 
days) after beginning the chemotherapy cycle. No patient 
developed clinical fluid retention. Chest radiograph and 
thoracic CT scan in all five patients showed bilateral 
diffuse interstitial infiltrates without pleural effusion. 
HRCT scan identified interstitial premonitis in two cases 
(patients 3 and 5). White-blood-cell count was normal 
(47OO-10,000 mm - 3, as was the platelet count (mean= 
250 x lo3 mm - ‘), Initial arterial blood gases on room air 
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showed hypoxaemia (mean PaO,, 60 mmHg; range 41-76), 
and hypocapnia (mean PaCO,, 33 mmHg; range 25-47). 
All five patients underwent fibreoptic bronchoscopic exami- 
nation. No endobronchial abnormalities were observed. 
Specific stains and cultures for bacteria, mycobacteria, 
fungi, cytomegalovirus, adenovirus, and respiratory syncy- 
tial virus were negative. The presence of human herpesvirus 
6 was not studied. The characteristics of cells recovered by 
bronchoalveolar lavage are summarized in Table 1. Four 
patients had a lymphocytic alveolitis with a lymphocyte 
proportion of more than 30% of the total alveolar cells. 
Alveolar lymphocytes were morphologically normal. Pneu- 
monitis occurred, while the non-Hodgkin’s lymphoma 
responded well to treatment, in all five cases, four patients 
showed complete response and one patient (no. 3) showed 
only partial response. 
Despite corticosteroid therapy with high dose methyl- 
prednisolone (240 mg day- ‘), two patients died 12 and 15 
days after onset of clinical signs. Post-mortem lung 
examination of patients 1 and 4 showed diffuse and exten- 
sive interstitial pulmonary fibrosis with lymphocytic 
interstitial infiltration and diffuse alveolar damage. 
No vasculitis, tumour infiltration or pathogens were found. 
Moreover, no residual lymphomatous involvement was 
found in other organs. Patient 2 remained stable with 
oral corticosteroids. In patient 3, pneumonitis followed 
a favourable course without corticosteroids, and the 
patient was able to receive two courses of aracytine 
without haematopoietic growth factor. Patient 5 improved 
dramatically within 2 days of prednisone treatment 
(60 mg day - i). 
Discussion 
In these five patients treated with the same chemotherapy 
regimen for non-Hodgkin’s lymphoma, we observed the 
development of acute febrile pneumonitis. The characteris- 
tics and course of the pneumopathy, and the role of the 
cytotoxic drugs call for comment. 
The five patients had febrile interstitial pneumonitis, 
characterized by abrupt onset within less than 48 h, lym- 
phocytic alveolitis in four of the five cases with an increased 
number of CD8+ cells in the three patients studied, occur- 
rence after two to four cycles of chemotherapy, and a highly 
unfavourable course as two out of the five patients died of 
respiratory insufficiency. 
A relationship between G/GM-CSF administration and 
the occurrence of pneumonitis has been previously sug- 
gested. Studies using G-CSF show conflicting results: eight 
cases of drug-induced pneumonia have been reported in 40 
patients with lymphoma who received G-CSF vs. none in 35 
patients treated with a similar chemotherapy regimen with- 
out G-CSF (6). A retrospective study reported four cases of 
drug-related pneumonitis in 12 patients treated with chemo- 
therapy and G-CSF for lymphoma vs. only one out of 24 
patients treated with a similar chemotherapy regimen but 
without CSF (7). Matthews (3) reported pulmonary toxicity 
in four out of five patients with Hodgkin’s disease treated 
with ABVD (doxorubicin, bleomycin, vinblastine and 
dacarbazine) and G-CSF. However, no difference in pul- 
monary toxicity has been detected between two groups of 
patients within non-Hodgkin’s lymphoma treated with 
G-CSF, (nine cases of pulmonary toxicity out of 139 
patients) or with placebo, (seven of 139 patients) (9) and in 
patients with advanced-stage germ cell tumours receiving 
bleomycin either with (10 pneumonitis cases out of 29 
patients) or without (10 of 57 patients) G-CSF (10). 
Cytotoxic drugs may contribute to the development of 
pneumonitis. Bleomycin has been the drug most frequently 
implicated as a cause of pneumopathy. Bleomycin has a 
high rate of pulmonary complication in patients with 
non-Hodgkin’s lymphoma. Bleomycin-associated pneumo- 
nitis is mainly chronic pulmonary fibrosis occurring over a 
critical dose, approximately 450-500 mg (11). The cumula- 
tive dose of bleomycin in our patients and in reported 
patients with Hodgkin’s disease and CSF-related pneumo- 
nitis was lower, ~100 mg (3). However acute bleomycin- 
induced hypersensitivity pneumonitis after doses as low as 
50 mg has been described (I 1). Most patients with acute 
pulmonary damage associated with bleomycin responded 
favourably to corticosteriods (11). Our five cases differ from 
this acute pulmonary-associated bleomycin toxicity because 
two of our patients and nine of 27 reported patients 
suffering from CSF-related pneumonitis died of respiratory 
failure. It is notable that none of our patients received 
thoracic radiation or suffered renal function impairment, 
which are known risk factors for increasing bleomycin 
pulmonary toxicity (11). 
Methotrexate may also be incriminated because it is 
known to cause interstitial pneumonitis, which is indepen- 
dent of both dose and route of administration (11). Analy- 
sis of bronchoalveolar lavage in methotrexate-associated 
pneumonitis found predominantly CD8’ lymphocytes, a 
result also found in our cases. However, peripheral blood 
eosinophilia is present in 40% of the cases, and acute 
methotrexate pneumonitis usually has a dramatic 
response to corticosteroid therapy, although a fulminant 
course has been documented in some patients. Another 
possibility is a reaction to cyclophosphamide. As a 
rule, a prolonged course of high dose cyclophosphamide 
precedes the development of pneumonitis, but cases of 
interstitial pneumonia have been reported after only a few 
courses of combination chemotherapy (11). To our 
knowledge, when not combined with mitomycin, 
vindesine has not been previously indicated in pneumonitis. 
The same is true for doxorubicin when not in combination 
with radiotherapy. Thus, we believe that a causal 
relationship of these two cytotoxic drugs is unlikely in 
lung disease. 
The pathogenesis of CSF-related pneumonitis is 
unknown, Several hypothesis may be evoked. 
1. Animal models have shown that haemopoietic growth 
factors promote synthesis of free radicals, which may 
contribute to fibrosis. Subcutaneous administration of 
GM-CSF to rats produced fibroblast proliferation with 
acquired a-smooth muscle actin expression (12). 
2. An immune mechanism independent from a direct CSF 
effect may be possible because G/GM-CSF-related 
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pneumonitis occurred at a point when the steroid com- 
ponents of the regimen are being withdrawn. The cy- 
tokine network disregulation induced by CSF may be 
implicated in the local immunopathogenesis of intersti- 
tial pneumonitis. The release of various cytokines by 
CSF may increase the production of TGF-fi, which has 
an important role in the pathophysiology of bleomycin- 
induced lung fibrosis (13). The increased number of 
alveolar CD8’ lymphocytes contrasts with the neu- 
trophilic alveolitis related to high levels of IL-8 after 
administration of GM-CSF (14). These findings 
are similar to the influx of cells into the lungs in hyper- 
sensitivity pneumonitis: early neutrophil alveolitis is ob- 
served soon after antigen challenge, followed by an 
increase of lymphocytes; mainly the CD8’ subsets (15). 
3. No patient developed fluid retention, suggesting pulmon- 
ary oedema as reported in a few cases of acute respirat- 
ory distress syndrome occurring with G-CSF treatment 
of drug-induced agranulocytosis (16). 
In conclusion, the prophylactic use of G/GM-CSF fol- 
lowing cytotoxic chemotherapy may be associated with the 
development of acute interstitial pneumonitis in patients 
with lymphoma. The CSF may activate the known pulmon- 
ary toxicity of these cytotoxic drugs. The occurrence of 
haematopoietic growth-factor-associated pneumonitis 
seems unpredictable. These uncommon adverse events 
highlight the importance of post-marketing surveillance 
studies and surveys for new drug products. 
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